For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another
Furthermore, the EMA has withdrawn the weight loss medication rimonabant, a selective cannabinoid type 1 receptor antagonist, due to its reported links to increased risks of depression and suicide [70]
Infused with berberine and chromium, our botanical patches support your healthy lifestyle with: Effortless usejust stick and go A natural, plant-based formula A simple addition to your daily routine Buy 2, Get 1 FREE
Take stock of what you're eating and when for at least the first few months, says Dr
Microdosing GLP-1s began emerging as a trend after Wegovy, an Ozempic competitor, was approved by the FDA for obesity in 2021
Arledge, a plastic surgeon
